Citra-Lock™
Advanced Protection
More efficient than Taurolidine-based locking solutions for preventing thrombotic dysfunction of tunnelled hemodialysis catheters. Recommended by ERBP and ASDIN guidelines.
Citra-Lock™ Range
Tri-sodium citrate based catheter lock solution
Key Benefits
- • Anti-clotting and antimicrobial
- • Safe for all catheter types
- • Maintains catheter patency
- • ERBP & ASDIN recommended
Complete Citrate Solution Range
Comprehensive range of high-concentrated tri-sodium citrate catheter lock solutions, recommended by European and American nephrology guidelines
Citra-Lock™ 4%
4%Standard concentration citrate lock solution recommended by ERBP and ASDIN guidelines. Most extensively studied with best benefit/risk ratio.
Packaging:
5ml vials, boxes of 20 units
Art. nr. 24060201
Citra-Lock™ S
Prefilled SyringeTwin-pack prefilled syringes for enhanced safety and simplified handling with Luer-Slip/Luer-Lock connector system.
Packaging:
2 x 2.5ml in 5ml syringe
Art. nr. 24060207
Citra-Lock™ 30%
30%High concentration solution with proven antimicrobial efficacy. Reduces biofilm formation and catheter-related infections significantly.
Packaging:
5ml vials, boxes of 20 units
Art. nr. 24060203
Citra-Lock™ 46.7%
46.7%Maximum concentration for severe complications. Proven MRSA management record at Royal London Hospital with significant infection reduction.
Packaging:
5ml vials, boxes of 20 units
Art. nr. 24060202
Proven Clinical Results
Reduction in thrombotic dysfunction vs. taurolidine
Annual savings at Royal London Hospital
Reduction in MRSA infection rates
Request Product Information
Get detailed technical specifications, clinical studies, and ordering information for our complete Citra-Lock range.
Proven Superior Performance
Backed by extensive clinical research including large-scale cohort studies and in vitro antimicrobial testing
Superior Antimicrobial Activity
In vitro studies demonstrate superior antimicrobial activity of trisodium citrate over heparin for catheter locking, effective against multiple pathogens.
Marcel C Weijmer et al., 2002Large Cohort Study
1,514-patient multicenter study shows significant reduction in catheter removal due to infection or malfunction (HR 0.34, 95% CI 0.19–0.64).
Van Roeden et al., BMC Nephrology 2021Guideline Recommended
Recommended in the European Renal Best Practice Guidelines (ERBP) and the American Society of Diagnostic and Interventional Nephrology (ASDIN).
International GuidelinesMajor Clinical Study
"The best solution down the line"
Large-scale observational study (1,514 patients) comparing taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients.
Key Clinical Outcomes
Reduced Catheter Removal
HR 0.34 for infection/malfunction combined
Lower Infection Risk
HR 0.36 for catheter-related infections
Improved Patency
HR 0.33 for catheter malfunction
Antimicrobial Efficacy Results
| Pathogen | Result | Efficacy |
|---|---|---|
| Staphylococcus aureus & epidermidis | Complete killing achieved with increasing TSC concentrations | 100% |
| E. coli & P. aeruginosa | Complete killing achieved with TSC 30% | 100% |
| Candida albicans | Significant growth inhibition with TSC 30% | Significant |
Source: Weijmer MC et al. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002
Mechanism of Action
Antimicrobial Properties
- Ca²⁺ and Mg²⁺ chelating effects
- Broad spectrum antimicrobial activity
- Biofilm formation prevention
Anticoagulant Properties
- Effective heparin replacement
- Maintains catheter patency
- Minimal systemic effects
Endorsed by Leading Organizations
ERBP
European Renal Best Practice Guidelines
ASDIN
American Society of Diagnostic and Interventional Nephrology
CE Marked
Medical Device Class IIb
Exclusive Distribution Partner
Macao Wuzhou Pharmaceutical International Trading Co., Ltd. is the exclusive distributor for Dirinco AG's Citra-Lock products
Company Information
Manufacturer
Dirinco AG - Leading innovator in catheter lock solutions with advanced anti-clotting and antimicrobial technologies.
Distribution Partners
澳门五洲药物国际贸易有限公司
Macao Wuzhou Pharmaceutical International Trading Co., Ltd.
Contact Information
澳门电厂巷22号亨达大廈地下AJ座
Travessa da Central Térmica no22 Edifício Hantec r/c "AJ", Macao
+853 6588 5387
info@droga.cn
Distribution Coverage
We hold exclusive distribution rights for Citra-Lock products across key regions in China, providing comprehensive coverage and local expertise.
Greater Bay Area
Shanghai
Hainan
Partner with Us
Join our network of healthcare providers and ensure access to the most advanced catheter lock solutions.
Contact Our Specialists
Have questions about Citra-Lock products? Our clinical specialists are here to help you find the right solution.
Send us a Message
Quick Contact
Phone
+853 6588 5387
info@droga.cn
Address
澳门电厂巷22号亨达大廈地下AJ座
Travessa da Central Térmica no22
Edifício Hantec r/c "AJ", Macao
Business Hours
* Emergency inquiries will be responded to within 24 hours
Fast Response Guarantee
Our clinical specialists typically respond to inquiries within 4-6 hours during business days.